ECSP18060875A - Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano - Google Patents

Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano

Info

Publication number
ECSP18060875A
ECSP18060875A ECSENADI201860875A ECDI201860875A ECSP18060875A EC SP18060875 A ECSP18060875 A EC SP18060875A EC SENADI201860875 A ECSENADI201860875 A EC SENADI201860875A EC DI201860875 A ECDI201860875 A EC DI201860875A EC SP18060875 A ECSP18060875 A EC SP18060875A
Authority
EC
Ecuador
Prior art keywords
diaza
spiro
oxo
derivatives
amino
Prior art date
Application number
ECSENADI201860875A
Other languages
English (en)
Inventor
Anita Wegert
Wolfgang Schröder
Sven Kühnert
Klaus Linz
Paul Ratcliffe
René Michael Koenigs
Ruth Jostock
Achim Kless
Thomas Koch
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of ECSP18060875A publication Critical patent/ECSP18060875A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano, su preparación y su uso en medicamentos, en particular en el tratamiento del dolor.
ECSENADI201860875A 2016-01-13 2018-08-13 Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano ECSP18060875A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16151015 2016-01-13

Publications (1)

Publication Number Publication Date
ECSP18060875A true ECSP18060875A (es) 2018-08-31

Family

ID=55129636

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201860875A ECSP18060875A (es) 2016-01-13 2018-08-13 Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano

Country Status (26)

Country Link
US (7) US20170197949A1 (es)
EP (1) EP3402782B1 (es)
JP (1) JP6917379B2 (es)
KR (1) KR20180097734A (es)
CN (1) CN108602778B (es)
AR (1) AR107359A1 (es)
AU (1) AU2017206911B2 (es)
BR (1) BR112018014301B1 (es)
CA (1) CA3011182A1 (es)
CL (1) CL2018001909A1 (es)
CO (1) CO2018008450A2 (es)
CY (1) CY1123366T1 (es)
DK (1) DK3402782T3 (es)
EA (1) EA034898B1 (es)
EC (1) ECSP18060875A (es)
ES (1) ES2821969T3 (es)
HR (1) HRP20201660T1 (es)
HU (1) HUE051642T2 (es)
IL (1) IL260488B (es)
LT (1) LT3402782T (es)
MX (1) MX379359B (es)
PT (1) PT3402782T (es)
RS (1) RS60855B1 (es)
SI (1) SI3402782T1 (es)
TW (1) TWI654181B (es)
WO (1) WO2017121650A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3402784T3 (pl) 2016-01-13 2020-09-21 Grünenthal GmbH Pochodne 3-((hetero-)arylo)-alkilo-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekanu
MX378995B (es) 2016-01-13 2025-03-11 Gruenenthal Gmbh Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
PL3722284T3 (pl) 2016-01-13 2025-03-31 Grünenthal GmbH Pochodne 3-((hetero-)arylo)-8-amino-2-okso-1,3-diazaspiro-[4.5]-dekanu
MX379201B (es) 2016-01-13 2025-03-11 Gruenenthal Gmbh Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
LT3402782T (lt) 2016-01-13 2020-10-12 Grünenthal GmbH 8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekano dariniai
WO2019039852A1 (ko) 2017-08-22 2019-02-28 주식회사 엘지화학 방열 소재 디스펜싱 장치의 결정방법
TWI827785B (zh) 2019-01-11 2024-01-01 德商歌林達有限公司 經取代的吡咯啶醯胺iii
CN110092790B (zh) * 2019-06-11 2020-07-24 东北农业大学 一种生物碱类化合物及其制备方法和应用
US20240400537A1 (en) 2023-04-25 2024-12-05 Gruenenthal Gmbh Cis-8-(3,5-difluorophenyl)-8-(dimethylamino)-1,3-diazaspiro[4.5]decan-2-one derivatives

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2734265B1 (fr) 1995-05-17 1997-06-13 Adir Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
AU2002303406B2 (en) 2001-04-18 2006-03-30 Euro-Celtique S.A. Nociceptin analogs
DE10130020A1 (de) 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
DE10135636A1 (de) * 2001-07-17 2003-02-06 Gruenenthal Gmbh Substituierte 4-Aminocyclohexanole
DE10210195B4 (de) 2002-03-07 2005-12-15 Schwarz Pharma Ag Verwendung von 1,3-Diazaspiro-[4,5]decan-2,4-dithion zur Behandlung von Schmerz
BR0312414A (pt) 2002-07-05 2005-05-10 Targacept Inc Compostos de n-aril diazaespirociclico e métodos para a preparação e uso dos mesmos
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
US20080287478A1 (en) 2003-05-23 2008-11-20 Lars Bo Laurenborg Hansen Nociceptin Analogues and Uses Thereof
JO2676B1 (en) 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
DE102005044813A1 (de) 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005023784A1 (de) 2005-05-19 2006-11-30 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102006019597A1 (de) 2006-04-27 2007-10-31 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
JP5079011B2 (ja) 2006-10-19 2012-11-21 エフ．ホフマン−ラ ロシュ アーゲー 糖尿病のための１１β−ＨＳＤ１阻害剤としてのイミダゾロン及びイミダゾリジノン誘導体
WO2008124209A1 (en) 2007-04-09 2008-10-16 Janssen Pharmaceutica, N.V. 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression
MX2010010407A (es) 2008-03-27 2010-10-25 Gruenenthal Gmbh Derivados de 4-aminociclohexanos sustituidos.
TW201038572A (en) 2009-03-25 2010-11-01 Gruenenthal Gmbh Substituted spiro-amide compounds
WO2010151815A2 (en) 2009-06-25 2010-12-29 Abbott Laboratories 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
TWI582092B (zh) 2010-07-28 2017-05-11 歌林達股份有限公司 順式－四氫－螺旋（環己烷－１,１’－吡啶［３,４－b］吲哚）－４－胺－衍生物
WO2014106238A1 (en) * 2012-12-31 2014-07-03 Fang, Qun, Kevin Heterocyclic compounds and methods of use thereof
WO2015136947A1 (en) * 2014-03-14 2015-09-17 Raqualia Pharma Inc. Azaspiro derivatives as trpm8 antagonists
MA40170A (fr) 2014-06-13 2017-04-19 Purdue Pharma Lp Dérivés hétérocycliques de morphinan et leur utilisation
PL3402784T3 (pl) 2016-01-13 2020-09-21 Grünenthal GmbH Pochodne 3-((hetero-)arylo)-alkilo-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekanu
MX378995B (es) 2016-01-13 2025-03-11 Gruenenthal Gmbh Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
PL3722284T3 (pl) 2016-01-13 2025-03-31 Grünenthal GmbH Pochodne 3-((hetero-)arylo)-8-amino-2-okso-1,3-diazaspiro-[4.5]-dekanu
MX379201B (es) 2016-01-13 2025-03-11 Gruenenthal Gmbh Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
AR107354A1 (es) 2016-01-13 2018-04-18 Bristol Myers Squibb Co Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock
HUE058647T2 (hu) 2016-01-13 2022-09-28 Novo Nordisk As Zsírsav szubsztituenseket tartalmazó EGF(A) analógok
LT3402782T (lt) 2016-01-13 2020-10-12 Grünenthal GmbH 8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekano dariniai

Also Published As

Publication number Publication date
US20230183222A1 (en) 2023-06-15
CY1123366T1 (el) 2021-12-31
JP2019501932A (ja) 2019-01-24
EP3402782B1 (en) 2020-07-29
EP3402782A1 (en) 2018-11-21
CN108602778A (zh) 2018-09-28
US20190375738A1 (en) 2019-12-12
JP6917379B2 (ja) 2021-08-11
MX2018008645A (es) 2018-11-19
BR112018014301A2 (pt) 2018-12-11
WO2017121650A1 (en) 2017-07-20
CO2018008450A2 (es) 2018-09-20
SI3402782T1 (sl) 2020-11-30
KR20180097734A (ko) 2018-08-31
DK3402782T3 (da) 2020-09-28
EA201891608A1 (ru) 2019-01-31
NZ745186A (en) 2024-05-31
US20170197949A1 (en) 2017-07-13
AU2017206911B2 (en) 2020-07-09
AR107359A1 (es) 2018-04-25
IL260488B (en) 2021-09-30
US20210179595A1 (en) 2021-06-17
CN108602778B (zh) 2021-12-10
HRP20201660T1 (hr) 2021-03-05
PT3402782T (pt) 2020-10-01
US20200399255A1 (en) 2020-12-24
LT3402782T (lt) 2020-10-12
HUE051642T2 (hu) 2021-03-01
EA034898B1 (ru) 2020-04-03
US10793556B2 (en) 2020-10-06
BR112018014301B1 (pt) 2023-10-31
TW201730155A (zh) 2017-09-01
AU2017206911A1 (en) 2018-08-30
RS60855B1 (sr) 2020-10-30
ES2821969T3 (es) 2021-04-28
CL2018001909A1 (es) 2018-10-19
TWI654181B (zh) 2019-03-21
US20180273516A1 (en) 2018-09-27
CA3011182A1 (en) 2017-07-20
MX379359B (es) 2025-03-11
US20190100515A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
ECSP18060875A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CL2018001624A1 (es) Antagonistas policíclicos del tlr7/8 y uso de los mismos en el tratamiento de trastornos inmunitarios
ECSP18060848A (es) Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[ 4.5]-decano
ECSP18060820A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
MX390014B (es) Compuestos de dinucleótidos cíclicos y métodos de uso.
ECSP18060864A (es) Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
ECSP18060834A (es) Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
CL2015002835A1 (es) Nuevos derivados de piridina
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
MX389026B (es) Una composicion farmaceutica y el uso de la misma.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2018002368A1 (es) Formulaciones de oritavancina
MX2016014701A (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
MX390441B (es) Formulaciones liquidas de fosfaplatino.
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.